✨
AI Summary
- Halloran Consulting Group discusses CGT development and regulatory challenges.
- Key issues include manufacturing complexity and clinical trial design.
- FDA focuses on off-target effects and requires robust gene editing data.
Guests on This Episode
MS
Monika Swietlicka
3 podcast appearances